Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
10 mai 2024 16h10 HE
|
Entera Bio Ltd.
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
08 avr. 2024 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the...
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
26 mars 2024 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
08 mars 2024 16h05 HE
|
Entera Bio Ltd.
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results...
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
04 mars 2024 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received...
Osteoporosis Drugs Market is Projected to Develop at a CAGR of 3.5% from 2023 to 2033 | Persistence Market Research
16 janv. 2024 03h00 HE
|
Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Market Overview: The Osteoporosis Drugs Market is a rapidly evolving sector within the pharmaceutical industry, primarily driven by the growing aging...
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
29 nov. 2023 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
14 nov. 2023 07h30 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
09 nov. 2023 14h30 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports...
Osteoporosis Treatment Market to Hit Market Size of US$ 16.6 Billion by 2030, Says a Market Report by RationalStat
09 nov. 2023 01h21 HE
|
Rationalstat LLC
Wilmington Delaware, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Global Osteoporosis Treatment Market is valued at US$ 12.0 billion in 2023 and is expected to grow at a significant CAGR of over 4.8% over the...